We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+59.2%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.69B
AUM Growth
+$748M
Cap. Flow
+$236M
Cap. Flow %
13.95%
Top 10 Hldgs %
59.6%
Holding
45
New
7
Increased
11
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$96.9M
2
BNR
Burning Rock Biotech
BNR
+$47.4M
3
GBIO
Generation Bio
GBIO
+$35.9M
4
BLFS icon
BioLife Solutions
BLFS
+$32.8M
5
ONC
BeOne Medicines Ltd
ONC
+$24.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$19.1M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$13.9M
3
GILD icon
Gilead Sciences
GILD
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$11.1M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.83%
2 Materials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
26
CRISPR Therapeutics
CRSP
$4.88B
$19.6M 1.16%
266,430
– –
GBT
27
DELISTED
Global Blood Therapeutics, Inc.
GBT
$18.9M 1.12%
300,000
– –
DMTK
28
DELISTED
DermTech, Inc. Common Stock
DMTK
$18.9M 1.12%
1,428,572
+856,859
+150% +$11.2M
ZLAB icon
29
Zai Lab
ZLAB
$2.05B
$15.6M 0.92%
190,000
– –
SGMO
30
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13M 0.77%
1,455,000
– –
GRTS
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12.3M 0.73%
1,850,373
-419,627
-18% -$2.83M
BDTX icon
32
Black Diamond Therapeutics
BDTX
$99.7M
$12.2M 0.72%
289,395
– –
ILMN icon
33
Illumina
ILMN
$30B
$11.1M 0.66%
30,840
– –
BMY.RT
34
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$10.6M 0.63%
2,950,000
+450,000
+18% +$1.62M
ORTX
35
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.9M 0.59%
165,000
+67,500
+69% +$6.18M
VYGR icon
36
Voyager Therapeutics
VYGR
$181M
$9.46M 0.56%
750,000
-345,075
-32% -$4.01M
ORIC icon
37
Oric Pharmaceuticals
ORIC
$1.1B
$8.48M 0.5%
+251,515
New +$8.03M
LEGN icon
38
Legend Biotech
LEGN
$3.68B
$5.75M 0.34%
+135,000
New +$5.27M
TPTX
39
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$4.84M 0.29%
75,000
– –
ZYME icon
40
Zymeworks
ZYME
$1.6B
$4.69M 0.28%
+130,000
New +$4.79M
DCPH
41
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.88M 0.23%
65,000
-75,000
-54% -$4.01M
STOK icon
42
Stoke Therapeutics
STOK
$1.84B
$2.86M 0.17%
120,000
– –
GILD icon
43
Gilead Sciences
GILD
$163B
– –
-175,000
Closed -$13.1M
SAGE
44
DELISTED
Sage Therapeutics
SAGE
– –
-385,000
Closed -$11.1M
GNMK
45
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-3,365,000
Closed -$13.9M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Casdin Capital held 45 positions worth $1.69B, up 79% from $942M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Casdin Capital deployed $236M of net new capital in Q2 2020, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Burning Rock Biotech: 173,079 shares worth $46.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 92% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $19.1M trimmed.

  • Casdin Capital's largest Q2 2020 buy was Burning Rock Biotech: 173,079 shares worth $46.7M.
  • Casdin Capital added most to Invitae Corporation in Q2 2020, an estimated $96.9M increase.
  • Casdin Capital's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $19.1M.
  • Casdin Capital fully exited GenMark Diagnostics, Inc in Q2 2020, selling an estimated $13.9M.
  • Casdin Capital's ten largest holdings make up 60% of its $1.69B portfolio in Q2 2020.
  • Casdin Capital opened 7 new positions and closed 3 in Q2 2020.
  • Casdin Capital's portfolio value rose 79% quarter-over-quarter to $1.69B.

Based on Casdin Capital's 13F filing for Q2 2020, filed 14 Aug 2020.